Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension Meeting Abstract

publication date

  • May 1, 2022

webpage

published in

start page

  • 14

end page

  • 15

volume

  • 63